Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Jul 16, 2009


Title: Genetic Inhibition by Double-Stranded RNA

Number: 7,560,438

Filed: Oct. 30, 2002

Lead Inventor: Andrew Fire, Carnegie Institution

The patent, its abstract states, claims "a process … of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo.

"The RNA has a region with double-stranded structure," the abstract adds. "Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical. The … invention is distinguished from prior art interference in gene expression by antisense or triple-strand methods."

Title: miR-16-Regulated Genes and Pathways as Targets for Therapeutic Intervention

Number: 20090175827

Dec. 31, 2007

Lead Inventor:
Mike Byrom, Asuragen

The invention, the patent application's abstract states, "concerns methods and compositions for identifying genes or genetic pathways modulated by miR-16, using miR-16 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient, and/or treating the patient with an appropriate miRNA."

Title: Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules

Number: 20090176723

Filed: Nov. 14, 2005

Lead Inventor: David Brown, Ambion (Applied Biosystems)

The invention, the patent application's abstract states, "concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the … invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library-screening assays."

Title: Chemically Modified Short Interfering Nucleic Acid Molecules that Mediate RNA Interference

Number: 20090176725

Filed: Aug. 17, 2006 PCT Filed: Aug. 17, 2006

Lead Inventor:
David Morrissey, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity. The … invention is also directed to compounds, compositions, and methods relating to traits, diseases, and conditions that respond to the modulation of expression and/or activity of genes involved in gene-expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases, and conditions.

"Specifically, the invention relates to double-stranded nucleic acid molecules … capable of mediating RNA interference against gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules," the abstract adds. "The … invention also relates to small nucleic acid molecules … that can inhibit the function of endogenous RNA molecules … or that can inhibit the function of RISC to modulate gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules.

"Such small nucleic acid molecules are useful, for example, in providing compositions to prevent, inhibit, or reduce diseases, traits, and conditions that are associated with gene expression or activity in a subject or organism," it notes.

Title: Double-Stranded RNA Structures and Constructs, and Methods for Generating and Using the Same

Number: 20090176727

Filed: Oct. 8, 2008

Lead Inventor:
Catherine Pachuk, Nucleonics (Alnylam Pharmaceuticals)

The invention "relates to novel double-stranded RNA structures and dsRNA-expression constructs, methods for generating them, and methods of utilizing them for silencing genes," according to the patent application's abstract. "Desirably, these methods specifically inhibit the expression of one or more target genes in a cell or animal without inducing toxicity … [and] can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides methods for identifying nucleic acid sequences that modulate a detectable phenotype, such as the function of a cell, the expression of a gene, or the biological activity of a target polypeptide."

Title: Treatment of CNS Conditions

Number: 20090176728

Filed: March 16, 2007 PCT Filed: March 16, 2007

Lead Inventor: Angela Sesto Yague, Sylentis

According to the patent application's abstract, the invention comprises "methods and compositions for the treatment of pathologic conditions of the central nervous system by means of intranasal administration of a composition that modulates, by means of RNA interference, the expression and/or activity of genes involved in above-mentioned conditions."

The application specifically cites the treatment of conditions including dementia and Alzheimer's, Huntington's, and Parkinson's diseases.

Title: Method of Treating Neurodegenerative Disease

Number: 20090176729

Filed: Dec. 12, 2008

Inventor: Pamela Tan, Alnylam Pharmaceuticals

"Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein gene expression, such as for the treatment of neurodegenerative disorders," the patent application's abstract states. "An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells."

Title: LNA-Modified Phosphorothiolated Oligonucleotides

Number: 20090176977

Jan. 29, 2007 PCT Filed: Jan. 29, 2007

Lead Inventor: Joacim Elmen, Karolinska Institutet (Santaris Pharma)

The invention, the patent application's abstract states, "provides oligonucleotides which comprise a dinucleotide consisting of a 5' locked nucleic acid, a phosphorothioate internucleoside linkage bond to a 3' RNA or RNA analogue. The dinucleotide reduces the strength of hybridization of the oligonucleotide to a complementary nucleic acid target.

"The modification can be used to modulate hybridization properties in both single-stranded oligonucleotides and in double-stranded siRNA complexes, particularly in oligonucleotides where the use of LNA results in excessively strong hybridization properties," the abstract notes.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.